Olaf Schouten.

These plots demonstrated parallel lines reasonably, indicating that the proportional-hazards assumption was not violated. Results of exploratory analyses for the principal outcome were evaluated by using tests for interaction of study-drug effect with baseline features. All analyses were performed based on the intention-to-treat basic principle. All statistical assessments were two-sided, and a P value of significantly less than 0.05 was thought to indicate statistical significance. Results Study Subjects Of 1669 patients assessed for trial eligibility, 1172 were excluded: 356 because they did not meet inclusion criteria, 798 because they were taking a statin already, and 18 for other reasons .This trial is specially critical due to its focus on adults coping with HIV. If we are effective, MVA85A can help make the imagine a world clear of TB a reality,’ said Fuad El-Hibri, Chief and Chairman Executive Officer of Emergent BioSolutions. ‘It really is great to start to see the vaccine applicant we initially developed at Oxford University reach this stage of medical trials,’ said Dr. Helen McShane, a Wellcome Trust Senior Clinical Study Fellow at the University of Oxford. ‘Within the next few years we should begin to get results on what effective the vaccine is definitely in protecting those people who are most at risk of TB.